Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Non Operating Investment Income came in at $24000.0 in Q1 2026, up 580.0% year-on-year from $3529.4 in Q1 2025, and up 442.86% quarter-over-quarter from -$7000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non Operating Investment Income history runs 9 years deep, the most recent figure standing at $24000.0 for Q1 2026.
- On a quarterly basis, Non Operating Investment Income rose 580.0% year-over-year to $24000.0 in Q1 2026; TTM through Mar 2026 was $21000.0, a 362.5% increase from a year earlier, with the FY2025 full-year figure at -$8000.0, changed 0.0% from the prior year.
- Non Operating Investment Income improved to $24000.0 in Q1 2026 per LCTX's latest filing, from -$7000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $40000.0 in Q1 2023 and bottomed at -$517000.0 in Q4 2022.
- The 5-year median for Non Operating Investment Income is -$6000.0 (2023), against an average of -$61200.0.
- Across the five-year window, Non Operating Investment Income tumbled 153.85% in 2025 and surged 580.0% in 2026, its largest moves.
- Year by year, Non Operating Investment Income stood at -$517000.0 in 2022, then soared by 98.84% to -$6000.0 in 2023, then jumped by 316.67% to $13000.0 in 2024, then sank by 153.85% to -$7000.0 in 2025, then surged by 442.86% to $24000.0 in 2026.
- Per Business Quant, the three latest LCTX Non Operating Investment Income figures stand at $24000.0 (Q1 2026), -$7000.0 (Q4 2025), and $6000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Dec 31, 2023 | -6,000.00 |